Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy

NCT02499224 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
39
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

CellabMED